Mercer Forms Strategic Alliance with Progyny to Offer Innovative Fertility Benefits

NEW YORK–(BUSINESS WIRE)–Mercer
announced today it has formed a strategic alliance with Progyny
to provide employers and their employees with the innovative SMART™
(Science and Member-Driven Assisted Reproductive Technology) fertility
benefit product which will enable companies to significantly reduce
newborn intensive care unit (NICU) and associated high-risk
maternity-related costs, while increasing access and positive outcomes.

The Progyny Suite of SMART Fertility Services includes a comprehensive
national network of fertility clinics; clinic quality and cost
transparency; and personal concierge services delivered by Patient Care
Advocates. Benefits include: egg freezing, IVF treatment, non-IVF
fertility treatments, and medications. In addition, genetic counselors,
fertility nurses, psychologists, and surrogacy counselors will be
available to patients for an end-to-end fertility solution. Employees
and employers will also have access to the Progyny Patient Portal with
over 250,000 pages of fertility information and education.

“Fertility benefits are becoming a key topic for employers and employees
alike,” said Dr. David Kaplan, leader of Mercer Health Innovation LABS.
“This interest is not only being driven by talent and retention-related
issues, but also by the high cost for employers who, whether they offer
infertility benefits or not, are still incurring much of the NICU and
associated high-risk maternity-related expenses. Progyny is helping both
employers and their employees better manage the financial and emotional
burden of infertility.”

“We’re proud that Progyny has developed a fertility benefit that
includes the latest fertility technology to greatly improve pregnancy
success,” said Karin Ajmani, President, Healthcare Services of Progyny.
“With one in six women in the US struggling with infertility, we know
these demands will continue to grow, and our benefit design coupled with
support services takes the guess work out of this emotional and often
costly journey. We’re thrilled that our alliance with Mercer won’t just
change lives, but help create healthy families.”

The Mercer strategic alliance with Progyny represents one of the
inaugural solutions brought to market by Mercer’s Health Innovation LABS
team. The Mercer LABS team continuously researches the health care
landscape, evaluates emerging trends and identifies promising solutions.
The LABS team engages with innovative companies to accelerate the
development of their ideas and test them with forward-thinking
employers. Their work helps employers navigate the rapidly changing
healthcare environment, launch clinically-impactful programs and improve
the health of their employees and families.

About Mercer

Mercer is a global consulting leader in talent, health, retirement and
investments. Mercer helps clients around the world advance the health,
wealth and careers of their most vital asset – their people. Mercer’s
more than 20,000 employees are based in 43 countries and the firm
operates in over 140 countries. Mercer is a wholly owned subsidiary of Marsh
& McLennan Companies
 (NYSE: MMC), a global professional services
firm offering clients advice and solutions in the areas of risk,
strategy and people. With annual revenue of $13 billion and 57,000
colleagues worldwide, Marsh & McLennan Companies is also the parent
company of Marsh,
a leader in insurance broking and risk management; Guy
Carpenter
, a leader in providing risk and reinsurance intermediary
services; and Oliver
Wyman
, a leader in management consulting. For more information, visitwww.mercer.com.
Follow Mercer on Twitter @Mercer.

About Progyny

Progyny is a best-in-class health care company providing consumers
effective fertility outcomes by aligning science, technology, clinics
and patients. Offering unique fertility solutions to consumers,
employers and health plans, Progyny is the first company with a
cost-efficient fertility benefit product to better manage women’s
fertility while reducing high maternity and NICU-related
costs. Progyny’s portfolio of solutions includes: Progyny Fertility
Benefits – the first cost-efficient fertility benefit solution for
employers and health plans, FertilityAuthority.com,
the country’s leading patient-matching technology platform serving the
fertility industry; EggBanxx.com,
a national network of over 185 top fertility doctors specializing in egg
freezing; and IVFAdvantage.com,
the only multi-cycle IVF savings program created by patients for
patients; and The Eeva™ Test, the first and only FDA-cleared test to aid
in embryo selection. Progyny is privately held and its investors include
Kleiner Perkins Caufield & Byers, TPG Biotech, SR One and MS Ventures.
The company is headquartered in New York, NY, with operations in Menlo
Park, CA. For more information, please visit http://www.progyny.com
and follow us on Twitter @Progyny.

Contacts

Mercer
Bruce M. Lee, +1-212-345-0553
bruce.lee@mercer.com